| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2009.27.9158 |
| P698 | PubMed publication ID | 20823406 |
| P50 | author | Jean-Luc Harousseau | Q3167165 |
| Michel Attal | Q57306384 | ||
| Herve Avet-Loiseau | Q61112732 | ||
| Thierry Facon | Q85789960 | ||
| Mohamad Mohty | Q86836425 | ||
| Philippe Moreau | Q87734443 | ||
| Mauricette Michallet | Q89534574 | ||
| Lotfi Benboubker | Q91591759 | ||
| Gerald Marit | Q99254932 | ||
| Claire Mathiot | Q114340053 | ||
| Frederic Maloisel | Q114412759 | ||
| Pascal Lenain | Q117252286 | ||
| Marie Odile Petillon | Q117252310 | ||
| Philippe Casassus | Q117252333 | ||
| P2093 | author name string | Cyrille Hulin | |
| Hervé Maisonneuve | |||
| Denis Caillot | |||
| Iain Webb | |||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| dexamethasone | Q422252 | ||
| multiple myeloma | Q467635 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 4621-4629 | |
| P577 | publication date | 2010-09-07 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial | |
| P478 | volume | 28 |
| Q45328412 | A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation |
| Q53116820 | A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis. |
| Q42781525 | A new standard of care in newly diagnosed multiple myeloma |
| Q49900433 | A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report |
| Q37700318 | A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma |
| Q33401596 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma |
| Q33412684 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma |
| Q57027518 | A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma |
| Q34307050 | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers |
| Q33405134 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma |
| Q36973229 | A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT |
| Q38807562 | A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. |
| Q39769576 | Advances in current treatment for patients with newly diagnosed multiple myeloma |
| Q27014801 | Advances in the autologous and allogeneic transplantation strategies for multiple myeloma |
| Q57904530 | Advances in the treatment of multiple myeloma |
| Q36000415 | Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party |
| Q38417073 | Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. |
| Q38227506 | An analysis of the safety profile of proteasome inhibitors for treating various cancers |
| Q35230189 | Approach to the treatment of multiple myeloma: a clash of philosophies. |
| Q92492646 | Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics |
| Q42184785 | Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation |
| Q48666333 | Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis |
| Q39295929 | Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy |
| Q42005212 | Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future |
| Q48058540 | Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. |
| Q39070193 | Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. |
| Q38385465 | Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial |
| Q42051905 | Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis |
| Q33558161 | Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial |
| Q38086014 | Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials |
| Q37908155 | Bortezomib for previously untreated multiple myeloma |
| Q37937699 | Bortezomib for previously untreated multiple myeloma |
| Q93144918 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later |
| Q24185881 | Bortezomib for the treatment of multiple myeloma |
| Q47604607 | Bortezomib for the treatment of multiple myeloma. |
| Q38096055 | Bortezomib for the treatment of previously untreated multiple myeloma |
| Q33982728 | Bortezomib in multiple myeloma: systematic review and clinical considerations |
| Q52686509 | Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. |
| Q33648344 | Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma |
| Q42781523 | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p |
| Q44510116 | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients |
| Q56971945 | Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study |
| Q90117531 | Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis |
| Q46432419 | Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis |
| Q42272171 | Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials |
| Q55058300 | Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. |
| Q37644930 | Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation |
| Q38234733 | Bortezomib-induced peripheral neurotoxicity: an update. |
| Q40285686 | Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma |
| Q37960157 | CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies |
| Q39390619 | Cancer immunotherapy: Breakthrough or "deja vu, all over again"? |
| Q36852225 | Challenges in multiple myeloma diagnosis and treatment |
| Q92233485 | Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials |
| Q40899348 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial |
| Q59353692 | Clinical significance of cancer-related fatigue in multiple myeloma patients |
| Q38578071 | Clinical treatment of newly diagnosed multiple myeloma |
| Q35180069 | Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r |
| Q39066209 | Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone |
| Q38833540 | Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma |
| Q38429817 | Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? |
| Q51772922 | Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. |
| Q38242006 | Controversies in multiple myeloma: to transplant or not? |
| Q37382627 | Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. |
| Q55359967 | Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. |
| Q28075297 | Cost-effectiveness of bortezomib for multiple myeloma: a systematic review |
| Q38218209 | Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. |
| Q38895167 | Current Review on High-Risk Multiple Myeloma |
| Q38087939 | Current approaches for the treatment of multiple myeloma |
| Q41819491 | Current approaches to the initial treatment of symptomatic multiple myeloma |
| Q64065748 | Current status of autologous stem cell transplantation for multiple myeloma |
| Q38209433 | Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. |
| Q47914097 | Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. |
| Q38412189 | Current therapeutic strategies for multiple myeloma |
| Q38072022 | Current therapeutic strategy for multiple myeloma |
| Q86554018 | CyBorD induction therapy in clinical practice |
| Q35794472 | Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results |
| Q96134056 | Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma |
| Q36767656 | Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma |
| Q92038498 | Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma |
| Q38107482 | Diagnosis and therapy of multiple myeloma |
| Q45412209 | Early mortality in multiple myeloma |
| Q51741922 | Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. |
| Q37162610 | Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma |
| Q82526829 | Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma |
| Q26767418 | Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis |
| Q55383806 | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. |
| Q38089497 | Efficacy of bortezomib as first-line treatment for patients with multiple myeloma |
| Q38037600 | Emerging biological insights and novel treatment strategies in multiple myeloma |
| Q37552008 | European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma |
| Q27005966 | European perspective on multiple myeloma treatment strategies in 2014 |
| Q35989943 | European perspective on multiple myeloma treatment strategies: update following recent congresses |
| Q27026478 | Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies |
| Q52663535 | Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. |
| Q26824498 | Fifty years of melphalan use in hematopoietic stem cell transplantation |
| Q26745957 | First line vs delayed transplantation in myeloma: Certainties and controversies |
| Q38148272 | Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials |
| Q51385709 | Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. |
| Q37875193 | Guidelines for the diagnosis and management of multiple myeloma 2011. |
| Q35569350 | Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities |
| Q34539519 | Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data |
| Q83000366 | Hematology: Bortezomib and dexamethasone induction for multiple myeloma |
| Q83667588 | Hematology: Setting the standard for newly diagnosed multiple myeloma |
| Q57904628 | High dose melphalan in primary systemic amyloidosis: status quo? |
| Q36750576 | High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma |
| Q53098336 | How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. |
| Q38115224 | IV. Initial treatment of multiple myeloma. |
| Q36525219 | Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. |
| Q61812339 | Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma |
| Q38738098 | Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. |
| Q46686111 | Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma |
| Q48227405 | Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma. |
| Q39466768 | Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States |
| Q37411236 | Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma |
| Q54480001 | Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. |
| Q26991817 | Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis |
| Q38661374 | Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials |
| Q36014687 | Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma |
| Q38597127 | Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past? |
| Q38176061 | Initial treatment of transplant-eligible patients in multiple myeloma |
| Q35802414 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation |
| Q83425696 | Is subcutaneous bortezomib ready for prime time? |
| Q38852886 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. |
| Q37515416 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial |
| Q38555091 | Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma |
| Q36525841 | Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients |
| Q45182114 | Low-risk identification in multiple myeloma using a new 14-gene model |
| Q38191975 | Maintenance therapy in newly diagnosed multiple myeloma: current recommendations |
| Q37425782 | Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine |
| Q38970595 | Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma |
| Q38131456 | Management of double-refractory multiple myeloma |
| Q38681463 | Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group |
| Q37970946 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. |
| Q37888716 | Managing multiple myeloma in the elderly: are we making progress? |
| Q35171777 | Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma |
| Q34147170 | Minor clone provides a reservoir for relapse in multiple myeloma |
| Q38756800 | Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes |
| Q36963203 | Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology |
| Q85840509 | Multiple myeloma |
| Q86407303 | Multiple myeloma |
| Q35061518 | Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy |
| Q37858327 | Multiple myeloma treatment strategies with novel agents in 2011: a European perspective |
| Q36777233 | Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management |
| Q44977303 | Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management |
| Q44470007 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q39471739 | Multiple myeloma: an update |
| Q40279004 | Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry |
| Q30240403 | Myeloma: management of the newly diagnosed high-risk patient. |
| Q64901832 | Navigating the treatment landscape in multiple myeloma: which combinations to use and when? |
| Q38613720 | Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia |
| Q37848037 | New developments in conditioning regimens before auto-SCT in multiple myeloma |
| Q38673764 | New pharmacotherapy options for multiple myeloma |
| Q38261677 | Novel agents and new therapeutic approaches for treatment of multiple myeloma. |
| Q26822754 | Novel agents for multiple myeloma to overcome resistance in phase III clinical trials |
| Q45297106 | Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials |
| Q38020248 | Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value |
| Q84781348 | Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma |
| Q28077567 | Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice |
| Q38833534 | Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation |
| Q33405532 | Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization |
| Q34788381 | Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. |
| Q38108391 | Perspectives in the treatment of multiple myeloma |
| Q33442798 | Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma |
| Q40616080 | Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma. |
| Q37274353 | Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma |
| Q44314310 | Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients |
| Q47899730 | Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial |
| Q33408056 | Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma |
| Q52868558 | Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. |
| Q37275721 | Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients |
| Q47353792 | Positioning of proteasome inhibitors in therapy of solid malignancies |
| Q37737800 | Posttransplant maintenance therapy in multiple myeloma: the changing landscape |
| Q92572416 | Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant |
| Q41002965 | Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance |
| Q92921561 | Proteasome Inhibitors for the Treatment of Multiple Myeloma |
| Q52958429 | Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. |
| Q53752929 | Proteasome inhibitors in cancer therapy. |
| Q38014395 | Proteasome inhibitors in multiple myeloma: 10 years later |
| Q92048980 | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies |
| Q61755948 | Radionuclide Therapy of Leukemias and Multiple Myeloma |
| Q64242177 | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| Q96138335 | Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma |
| Q84212818 | Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens |
| Q51833653 | Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. |
| Q90720842 | Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma |
| Q36839385 | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group |
| Q44279549 | Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy |
| Q41905576 | Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy |
| Q38000078 | SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma |
| Q41849927 | Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma |
| Q38059253 | Sequential or combination therapy for multiple myeloma |
| Q36570225 | Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents |
| Q36562341 | Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma |
| Q36182653 | Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials |
| Q43081275 | Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. |
| Q36852229 | Stem cell transplantation for multiple myeloma: current and future status |
| Q91672350 | Stem-cell transplantation in multiple myeloma: how far have we come? |
| Q33394981 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study |
| Q56970106 | Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation |
| Q36251560 | Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy |
| Q99589579 | Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma |
| Q39397389 | Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial |
| Q37842346 | Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma |
| Q37414394 | The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma |
| Q37150733 | The Diagnosis and Treatment of Multiple Myeloma |
| Q36444233 | The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma |
| Q37644252 | The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma |
| Q28539605 | The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma |
| Q38187476 | The emerging role of carfilzomib combination therapy in the management of multiple myeloma |
| Q33917164 | The future of autologous stem cell transplantation in myeloma |
| Q38246060 | The future of proteasome inhibitors in relapsed/refractory multiple myeloma. |
| Q53130957 | The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. |
| Q48102038 | The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. |
| Q38192044 | The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. |
| Q37205591 | The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma |
| Q36523810 | The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity |
| Q64967112 | The pharmacologic management of multiple myeloma in older adults. |
| Q39264310 | The possible role of burden of therapy on the risk of myeloma extramedullary spread |
| Q47339695 | The proteasome and proteasome inhibitors in multiple myeloma |
| Q95650650 | The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |
| Q42459032 | The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma |
| Q38375463 | The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents |
| Q30248842 | The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q38252583 | Therapeutic advancements in multiple myeloma |
| Q42119285 | Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients |
| Q88294502 | Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma |
| Q26851202 | Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers |
| Q83975326 | Treatment of multiple myeloma |
| Q37851855 | Treatment of newly diagnosed multiple myeloma in transplant-eligible patients |
| Q38316150 | Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. |
| Q30409713 | Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma |
| Q38255333 | Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back |
| Q37946701 | Update on risk stratification and treatment of newly diagnosed multiple myeloma. |
| Q33440007 | Update on the optimal use of bortezomib in the treatment of multiple myeloma |
| Q42357639 | Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma |
| Q36936514 | Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma |
| Q48121739 | Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. |
| Q38115226 | VI. Autologous stem cell transplantation and maintenance therapy |
| Q37128664 | Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients |
| Q82374037 | Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de |
| Q86479003 | [Bortezomib-based four-drug combination regimen improved the efficacy of multiple myeloma patients receiving previous doublet or triplet regimens containing Bortezomib] |
| Q54447945 | [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma]. |
| Q90527991 | [First-line treatment of multiple myeloma] |
| Q87195944 | [Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myiloma] |
Search more.